Biotech Values

[DewDiligence]

>Pfizer announced plans to cut its U.S. sales force by 20%, an acknowledgement that its current model for marketing drugs to doctors is too expensive.<

It’s about time. McKinnell had hinted that he would cut the salesforce, but he never did to any material degree.

This is a good development for some other Big Pharma, who may now decide to make corresponding cuts in their salesforces.

NVS is a notable exception: they are adding 20 % to their U.S. salesforce because they have several big launches and rollouts coming up.